Overall, we prospectively enrolled 65 patients affected by localized/locally advanced Her2+ BC and treated with trastuzumab-based neoadjuvant therapy followed by surgery in order to evaluate the predictive value of Hippo pathway transducers (TAZ/YAP) and specific cell metabolism regulators (AMPK/HMGCR/SCD1) for pCR. The gene discussed is SCD; the disease is breast cancer.